Affected by Hurricane Maria, Haizheng Pharmaceuticals is back out of stock

On September 3rd, Haizheng Pharmaceuticals issued an announcement on the supply of products (Rui Yining) from its controlling subsidiary, Hanyu Pharmaceutical Co., Ltd., and in late May 2018, Hanyu Pharmaceuticals received a notification from Pfizer that its Puerto Rico plant had been affected by Hurricane Maria at the end of last year, causing serious damage to production capacity, resulting in a certain degree of supply tension in the Chinese market.
it is learned that the semi-finished drug is produced by Pfizer's Puerto Rico plant, the original shareholder of Hanyu Pharmaceuticals, and then imported into China by Pfizer Dalian plant packaging for sale.
in late May 2018, Hanyu Pharmaceuticals received notification from Pfizer that its Puerto Rico plant had been severely damaged by Hurricane Maria late last year, resulting in a degree of supply constraints for Refinan finished products in the Chinese market. Production at the Puerto Rico plant is now steadily recovering and is expected to address the shortage by the end of the year, and Pfizer will continue to supply Reynin products steadily to Hanyu.
2017 sales revenue was RMB182.8268 million, accounting for 1.73% of 2017 operating income, and gross margin was RMB94.6786 million, accounting for 2.84% of total 2017 gross margin.
to date, other Pfizer products sold by Hanyu Pharmaceuticals have not been affected, and this phased supply shortage at Rayaning will not affect Hanyu Pharmaceuticals' full-year revenue and profit targets. (Mi Net)